Zydus Told To Conduct Phase III Trial in India for Lurbinectedin Injection, BE Study Waived
New Delhi: Zydus Lifesciences Limited has been directed to conduct a Phase III clinical trial in the Indian population for its proposed oncology drug Lurbinectedin Injection 4 mg/vial, following a review by the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO).
The recommendation came during the SEC meeting held on 17 July 2025 at CDSCO headquarters in New Delhi, where the company had submitted a proposal seeking permission to manufacture and market Lurbinectedin in India. As part of its submission, Zydus also requested a waiver of both local clinical trials and bioequivalence (BE) study requirements.
Lurbinectedin is a selective inhibitor of oncogenic transcription, approved in several countries including the United States, primarily for the treatment of relapsed small cell lung cancer (SCLC). It functions by inhibiting RNA polymerase II, leading to DNA strand breaks and subsequent cancer cell death. Given the global approvals and its role in treating aggressive cancers, Zydus had proposed introducing the drug in India without additional local studies.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.